长期口服恩替卡韦治疗的慢性乙型肝炎患者换用α干扰素治疗临床疗效随访研究

doi:10.3969/j.issn.1672-5069.2018.05.017

Abstract

Wang Fangfang, Zhang Guofan, Guo Chunxia, et al.. Clinical efficacy and safety of switching from entecavir to interferon-α in patients with hepatitis B[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(5): 721-724.

References

[1] 中华医学会肝病学分会和感染病学分会. 慢性乙型肝炎防治指南(2015 更新版).实用肝脏病杂志,2016,19(3):Ⅴ-XXⅢ.
[2] Geneva:World Health Organization. Guidelines for the prevention,care and treatment of persons with chronic hepatitis B infection. Free Books & Documents,2015.
[3] Yapali S,Talaat N,Lok AS.Management of hepatitis B:our practice and how it relates to the guidelines. Clin Gastroenterol Hepatol,2014,12(1):16-26.
[4] Liaw YF,Sung JJ,Chow WC,et al.Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med,2004,351(15):1521-1531.
[5] Marcellin P,Gane E,Buti M,et al.Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B:a 5-year open-label follow-up study. Lancet,2013,381(9865):468-475.
[6] Reijnders JG,Perquin MJ,Zhang N,et al.Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B. Gastroenterology,2010,139(2):491-498.
[7] Jeng WJ,Sheen IS,Chen YC,et al.Off-therapy durability of response to entecavir therapy in hepatitis B e antigen-negative chronic hepatitis B patients. Hepatology,2013,58(6):1888-1896.
[8] Seto WK,Hui AJ,Wong VW,et al.Treatment cessation of entecavir in Asian patients with hepatitis B e antigen negative chronic hepatitis B:a multicentre prospective study. Gut,2015,64(4):667-672.
[9] 周岳进,郑金莉, 肖扬等. 拉米夫定治疗CHB患者停药后病情加重的综合处理. 实用肝脏病杂志,2003,6(4):237-238.
[10] Nicole A,Weerd D,Nguyen T.The interferons and their receptors-distribution and regulation. Immunol Cell Biol,2012,90(5):483-491.
[11] Liaw YF,Kao JH,Piratvisuth T,et al.Asian-Pacific consensus statement on the management of chronic hepatitis B:a 2012 update. Hepatol Int,2012,6(3):531-561.
[12] Michailidis E,Kirby KA,Hachiya A,et al.Antiviral therapies: focus on hepatitis B reverse transcriptase. Int J Biochem Cell Biol,2012,44(7):1060-1071.
[13] Ji M,Hu K.Recent advances in the study of hepatitis B virus covalently closed circular DNA. Virol Sin,2017,32(6):454-464.
[14] Schreiner S,Nassal M.A role for the host DNA damage response in hepatitis B virus cccDNA formation-and beyond. Viruses,2017,9:125.
[15] Zeisel MB,Lucifora J,Mason WS,et al.Towards an HBV cure: state of-the-art and unresolved questions-report of the ANRS workshop on HBV cure. Gut,2015,64:1314-1326.
[16] Nassal M.HBV cccDNA:viral persistence reservoir and key obstacle for a cure of chronic hepatitis B. Gut,2015,64:1972-1984.
[17] Lu F,Wang J,Chen X,et al.Potential use of serum HBV RNA in antiviral therapy for chronic hepatitis B in the era of nucleos(t)ide analogs. Front Med,2017,11(4):502-508.
[18] Wang J,Sheng Q,Ding Y,et al.HBV RNA virion-like particles produced under nucleos(t)ide analogues treatment are mainly replication-deficient. J Hepatol,2017,78(17):324-331.
[19] van Campenhout MJH,van Bmmel F,Pfefferkorn M,et al. Host and viral factors associated with serum hepatitis B virus RNA levels among patients in need for treatment. Hepatology,2018[Epub ahead of print].
[20] Pei RJ,Chen XW Lu MJ. Control of hepatitis B virus replication by interferons and Toll-like receptor signaling pathways. World J Gastroenterol,2014,20(33):11618-11629.
[21] Haller O,Staeheli P,Kochs G.Interferon-induced Mx proteins in antiviral host defense. Biochimie,2007,89:812-818.
[22] Samuel CE.Antiviral actions of interferons. Clin Microbiol Rev,2001,14:778-809.
[23] Lucifora J,Xia Y,Reisinger F,et al.Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA. Science,2014,343:1221-1228.
[24] Biron,CA.Role of early cytokines, including alpha and beta interferons IFN-(α/β),in innate and adaptive immune responses to viral infections. Semin Immunol,2016,5:383-390.
[25] Martinot-Peignoux M,Lapalus M,Asselah T,et al.HBsAg quantification:useful for monitoring natural history and treatment outcome. Liver Int,2014,34(Suppl 1):97-107.
[26] Belloni L,Allweiss L,Guerrieri F,et al.IFN-α inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome. J Clin Invest,2012,122:529-537.

Clinical efficacy and safety of switching from entecavir to interferon-α in patients with hepatitis B

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	chronic hepatitis B Zhu Lingyun, Zhang Maohai Cui Shasha, et al.. Serum IL-12 and IL-18 levels as well as peripheral blood mononuclear cell FOXp3 in patients with [J]. Journal of Practical Hepatology, 2019, 22(6): 816-819.
[2]	patients with chronic hepatitis B Zhang Yingming, Shen Shuang, Tian Fei, et al.. Prediction of response to peginterferon alfa-2a by blood IFNL4 and IL-28B gene polymorphisms in [J]. Journal of Practical Hepatology, 2019, 22(6): 828-831.
[3]	Li Chuanjie, Xu Jing, Wang Liangliang, et al.. Changes of serum HBsAg levels in patients with chronic hepatitis B receiving entecavir treatment [J]. Journal of Practical Hepatology, 2019, 22(6): 928-929.
[4]	Gao Wei, Hou Yong. Diagnostic efficacy of hepatic fibrosis by liver stiffness measurement in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 652-655.
[5]	Bai Yichun, Deng Jihong, Mei Xiaoping. Efficacy of peginterferon alfa-2b treatment and affecting response factors in patients with chronic hepatitis B [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 490-493.
[6]	Li Gaoming, Lyu Bihua. Effect of combination of entecavir and herbal medicine on negative emotion in patients with chronic hepatitis B and depression [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 498-501.
[7]	Zhang Yafei, Ye Jun, Xie Qinxiu, et al. Difference in predicting efficacy of significant liver fibrosis by noninvasive liver fibrosis index in different hospitals [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 510-513.
[8]	Wang Baodan, Li Meng, Gao Yu. Predictive factors of response to interferon-α antiviral therapy in children with chronic hepatitis B [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(3): 345-348.
[9]	Yang Ruixi, Liu Mingxin, Chen Lingxi. Efficacy and safety of tenofovir disoproxil fumarate and entecavir in the treatment of chronic hepatitis B patients with viral DNA polymerase 204 site mutation infection [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(3): 349-352.
[10]	Gu Sunzedong, Yang Xiaofei, Zhang Peixin. Changes of serum and hepatic fibrinogen-like protein 2 levels in patients with chronic hepatitis B and hepatitis B cirrhosis after receiving entecavir therapy [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(3): 405-408.
[11]	Jiang Yi, Liu Bing. Comparison of clinical features and histopathological activity index between patients with chronic hepatitis B and chronic hepatitis C [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 188-191.
[12]	Cao Yanping, Sui Hongting, Pan Meng, et al.. Efficacy of entecavir and peg-IFNα-2a or thymosin α1 combination in the treatment of patient with compensated hepatitis B liver cirrhosis [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 93-96.
[13]	Hu Hulan, Zhu Mengfei, Shi Junping.. Non-alcoholic fatty liver disease with concurrent chronic hepatitis B: What’s the progress [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 149-152.
[14]	Wang Yaofeng.. Efficacy and safety of tenofovir in the treatment of patients with chronic hepatitis B [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(6): 847-850.
[15]	Huang Chunming, Yang Zhan, Nie Yuqiang, et al.. Prediction of liver fibrosis by gamma-glutamyl-transpeptidase-to-platelet ratio in patients with chronic hepatitis B viral infection with normal serum transaminase levels [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(6): 859-862.